contains inpatient/ambulatory claims, prescription claims, and demographic data for all beneficiaries. The current study used medical claims data and registration data retrieved from the NHIRD for [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] . The protocol for this study was approved by the Institutional Review Board of Kaohsiung Medical University Hospital (KMUH-IRB-980174).
Study Population
We identified all patients eighteen years old or older diagnosed with schizophrenic disorders (ICD-9-CM code: 295), mood disorders (ICD-9-CM code: 296), or dementia (ICD-9-CM code: 290, 331.0) later found to have an AMI incident (ICD-9-CM code: 410). Patients with these disorders were selected because they are commonly prescribed antipsychotic medications. 10, 14 For patients to be included, they had to have received no myocardial infarction related diagnoses (ICD-9-CM code: 410, 411.0, 412) from January 1, 1997 to the date of AMI event leading to hospital admission or emergency department visit in 1999-2009. To ensure new cases of AMI were being identified, patients with concomitant diagnosis of cardiomyopathy (ICD-9-CM code: 425), pericarditis (ICD-9-CM code: 420), aortic dissection (ICD-9-CM code: 441), or coronary aneurysm (ICD-9-CM code: 414.11) were excluded. Patients were also excluded if they had been only prescribed prochlorperazine, an agent commonly used as an antiemetic rather than an antipsychotic.
Case-Crossover Design
A case-crossover design was used to compare antipsychotic exposure for the same patient within a case period (the 1-to 30-day period before the AMI event) with exposure within the control period (the 91-to 120-day period before the event). 11 This self-controlled method reduces the possibility of within-person time-invariant confounding (e.g., lifestyles, genetic profiles, and body characteristics affecting the pharmacokinetics of antipsychotics) and separates acute effects ) w w wer er e e e e ex ex excl cl c ud ud uded ed ed. . Pa Pa ati ti tien en ents ts ts w w wer er ere al al a so so so e e exc xc xclu lu l de de ded d d if if if t t the h h y had been n from more chronic effects of an antipsychotic exposure. 13 This approach also avoids control selection biases associated with traditional case-control designs. 13 Since 1988 when the casecrossover design was originally developed to study immediate triggers for AMI, 15 several studies have used it to study risk of stroke after use of antipsychotics or antidepressants as well as risk of AMI after use of analgesics. [16] [17] [18] For comparison purposed, this study uses the same definitions of time window (30 days) and time frame as those adopted in previous studies of antipsychotics. 11, 16 Exposure to Antipsychotics
Antipsychotic use was defined if a patient received at least one antipsychotic prescription (Anatomical Therapeutic Chemical [ATC] code: N05A) for one day during the case or control period. 19 Dividing the cumulative prescribed doses into the total number of days supplied during the case or control period allowed the calculation of mean daily dose. Risk of AMI was examined with three mean daily dose ranges (<90, 90-180, and >180 chlorpromazine-equivalent doses).
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Within-Patient Time-Variant Confounding Factors
For each subject, factors that could potentially change across the case and control periods were identified and analyzed. These included number of outpatient visits (a measure of healthcare utilization) and the prescriptions of concomitant medications potentially related to AMI, mu mu ult lt l ip ip iply ly lyin ing g g th th the e me me mean an d da ai aily ly d d dru ru r g g g co co con nc nce en entr tr trat at ati i ion n n (h (he er ere e to to ota ta al l l hu h hum ma man n n bl bl bloo oo o d d d v vo volu lu ume me me w w was as s as s ssu um umed ed d t t to o be five liters s 22 22 22 ) ) ) of of of a a an n n an an anti t t ps ps syc yc ycho ho oti ti tic c by by b i i its ts t o o ora ra ral l l bi bi b oa oa o va va vail ilab ab bi i ili li ity ty ty, , de de defi fi f ne e ed d d as as as t t the he he f fra ra act ct ctio io ion n n of o o an orally--- 
Statistical Analysis
Conditional logistic regression was used to estimate the association between risk of AMI, use of antipsychotics and binding to receptors. The crude odds ratio (OR) and the adjusted OR (AOR)
were calculated, comparing the odds of antipsychotic exposure between the 1-30 day (case period) and the 91-120 day (control period) before the AMI event. The adjustments controlled for the effects of outpatient visits and concomitant medications across these two periods. Several sensitivity analyses were performed to examine the robustness of the results. First, the current model was compared with other models of different control periods and time windows: time frame 1 (case/control period=1-30/61-90 days), time frame 2 (case/control period=1-30/121-150 days), 14-day window (case/control period=1-14/91-104 days), and 7-day window (case/control period=1-7/91-97 days). Second, because diabetes mellitus, hypertension or hyperlipidemia status might change within the study time frames, models with and without adjustments for the presences of these diagnoses in case and control periods were compared. Third, we evaluated the impact of changes in threshold for the definition of AMI on our results using different criteria for subject enrollment. Because AMI and unstable angina belong to the same spectrum of clinical manifestations attributed to obstruction of the coronary arteries, we conducted a separate analysis for patients without a history of unstable angina (ICD-9-CM code: 411.1) prior to the incident AMI. Because an AMI event requires immediate medical attention, we also repeated the models for only patients who received several treatments specifically indicated for AMI within 30 days he effects of outpatient visits and concomitant medications across these two peri ri iod od ods. s S S Sev v ever er eral a al ensitivity analyses were performed to examine the robustness of the results. First, the current mo mode de del l l wa wa was s s co co omp p par ar ared e with other models of differ er ren en e t t control period od ds an and d d ti ti t me windows: time f fr ram m me 1 (case/ /co cont ntro rol l l pe pe eri ri riod od od=1 =1 =1-3 -30 0/ 0/6 61 61--9 90 0 0 da ays ys s), ti im me f fra ra rame me 2 2 ( (ca ca ase e e/c /con on ntr rol ol p p pe er erio iod= d= d=1-1-1 30 30 were further excluded. We were left with 56,910 patients subsequently treated for AMI. Patient year before the AMI. The interactions between these characteristics and antipsyc ch ho hoti ti t c us u use e e we we were re examined by likelihood ratio tests. To determine the most significant receptor binding associated wi with th h a a an n n an an nti ti tips psyc cho ho hoti tic-related AMI, stepwise regr gr gres es e s sion procedure e e was as u u us se sed with variable e ele e ect c ion criter eria ia ia set et a at t P P P<0 <0 <0.0 .0 05 5 5 fo for r r b bo both h h e e entry y y i i into a an nd re re remo mo ova a al l fr fr ro om m t the he h r r reg eg gre re ress ssio io on n n m mo mode de el. l l. A A All l demographic and clinical characteristics are summarized in Tables 3 & 4) . There was no important interaction of antipsychotic use with co-medications on the risk of AMI. The association between AMI risk and use of two negative controls (benzodiazepine drugs and nonbenzodiazepine hypnotics) was not significant (AOR=1.03, 95% CI=0.92-1.15; AOR=1.06, 95% CI=0.95-1.18; respectively).
As seen in Table 3 and Supplemental Figure 1 , the highest risk of AMI was found with amisulpride (AOR=5.65, 95% CI=2.97-10.76). Supplemental Table 5 shows the confounding effects of various covariates on the association with AMI risk. 
001).
Reanalysis of the data using two othe he er r ti ti ime me e f f fra ra rame me m s s and time windows as well as different input variables and subject inclusion criteria generated i imi mi mila la lar r r re resu su sult lt lts s (Su Su Sup pp pplemental Tables 3 & 4) . T Th he her re e was no impo ort r r an nt t in in int teraction of an nti i ips p ychotic us use e e w wi with th th c co o-o-me me medi d dica cati ti t o on ons s o on n th he r risk k o of f A A AMI M MI. Th Th The e a a ass soci ci iat a atio o on n be be bet tw twee ee en n AM AM AMI I I ri risk sk sk a and us use e e of of of t t two wo n n ne eg egat ativ ive e co co ont nt tro rols s ( ( (be be enz nz nzod od odia ia aze ze epi pi pin n ne dr dr drug ug ugs s an an nd d no no nonb nb nben en e z zo zodi di diaz az a e ep epin ine e hy hy hypn pn pnot ot oti i ics) s) ) w w was as n no ot ot 
P<0.0001).
Discussion
This study found antipsychotic use in patients with schizophrenia, mood disorders, or dementia to be significantly associated with risk for AMI. The risk was dose-dependent and increased in short-term users, male patients, elderly patients, and patients with dementia. Physically healthier patients with no preexisting diabetes mellitus, hypertension, or dyslipidemia had greater risk, largely because physicians were less likely to restrict common dosages of antipsychotic prescription for these patients. The AMI risk of antipsychotic use appeared to be specifically associated with D 3 receptor blockades by antipsychotics.
Our findings of this association between the risk of AMI and use of antipsychotics are consistent with previous cohort and case-control studies. 3, [7] [8] [9] 11 This case-crossover study provides new evidence that antipsychotics may pose significantly higher risk for AMI in shorteceptor antagonism actually predicted the risk for AMI (AOR=2.59, 95% CI=2. 2.4 43 43-2 -2 -.7 .7 75, 5, 5,
P<0.0001).
D Disc c scussion
Th Th his is is s s stu tu tudy dy dy f f fou o ound nd d a a ant ntip ip psy y ych chot ot tic ic u u use se se i i in n pa pa pati ti tien en ents s w w wit it th h s sch ch hiz iz zop op ophr hr ren en e i ia ia, mo mo m od od od d dis is sor or orde de d rs rs rs, , , o or d de em emen en nti i ia a o be signific can an antl tl t y y y as as asso so oci c c at t ted ed ed w wit it ith h h ri ri risk sk f f for or r A A AM M MI. I. I T T The he he r ris sk k k wa wa was s s do do dose s -d -d -dep ep epen en ende de dent nt a a and nd nd i i inc nc ncreased in term users ( 30 days in the year before AMI). This finding may partially explain the reason that one previous case-control study, 28 which used a long study time window (90 days), did not find an association between antipsychotic use and AMI risk. Such a study design could possibly mix the immediate severe rapidly passing effects of antipsychotics with their long-term effects, which would reduce the risk estimates. The relatively lower risk of AMI observed in more chronic antipsychotic users might be related to the effects of tolerance and cross-tolerance to antipsychotic drugs. 29 We suggest a prospective cohort study be conducted to further investigate whether such time-dependent risk exists and to determine safer ways of prescribing antipsychotic medications.
We found male patients, older patients, and those with dementia to be at higher risk for AMI when prescribed antipsychotics ( Table 4) . This elevated risk might be explained by sexand age-related differences in blood levels of estrogen/cholesterol. 30 We also found physically healthier patients with no preexisting diabetes mellitus, hypertension, or dyslipidemia to be at possibly increased risk of AMI when treated with antipsychotics (Table 4) , though this finding was likely to be explained by the fact that these patients had been exposed to significantly higher doses of antipsychotics (P<0.001) with greater increases in dosing adjustments (P<0.001) before the AMI events. We observed a dose-dependent effect on AMI risk ( Table 2, and Supplemental   Tables 3 & 4) , suggesting possibly that the increased amount of drugs that these healthier individuals received could have increased their risk for AMI. Our finding of a lower immediate risk for AMI in patients who received lower doses in the short-term but who had a higher baseline metabolic risk indicates that our case-crossover design indeed enabled us to separate the antipsychotic's acute effects on AMI risk from its chronic effects mediated by a metabolic disorder.
We found male patients, older patients, and those with dementia to be at h h hig ig ghe he h r r r ri ri risk sk sk f f for or AMI when prescribed antipsychotics ( Table 4) . This elevated risk might be explained by sexan nd d d ag ag age e-e-re re ela la late te ted di di dif ff ffe erences in blood levels of es str tr trog og gen/cholesterol ol l. . 30 W W We e e a also found physically h he heal al lth t ier patien ents ts s w w wit ith h h no no no p p pre re ee ex exis isti ti tin ng ng d d dia a abet te es s me ell li itus, s, s, h h hyp yp per rte ten n nsi io on, n o o or dy dy ysl s sli ip ipid idem em emia ia ia t to o be b be a at t po poss ss ssib ib ibly ly ly i inc nc ncre r reas ased ed ed r ris isk k k o of of A AM MI MI w w wh h hen e en t tre re r at at ated ed ed w w wit it i h h h an an nti ips ps psyc yc ych ho hoti ti tics cs s (Ta Ta Tabl bl le 4 4 4), ), t t tho ho oug ug ugh h h t t this is s f f fin in i di di ing g g was likely to o be be be e exp xp xpla la l in in ined ed b b by y y th h he e e f fac ac ct t th th hat at t t the he hese se se p p pat at atie ie ent nts s s ha ha had d d be be been en en f f f f ex ex expo po pose se sed d d to to t s s sig ig igni ni n fi fi f ca ca c ntly higher r
In addition to AMI, ventricular arrhythmia and sudden cardiac death have also been reported to be associated with antipsychotic use. 31 Because most sudden cardiac deaths are caused by ventricular fibrillation secondary to AMI, 32 we hypothesize that an antipsychoticrelated AMI could possibly serve as a sentinel event setting in motion a chain of these serious adverse cardiovascular events. However, further study is needed to investigate the relationship between antipsychotic use and sudden cardiac death, which could also represent an additionally great diversity of cardiac events associated with antipsychotic drugs.
Although it is not known through which mechanism antipsychotic use may influence the risk for AMI, this study found D 3 receptor antagonism to be the most likely pharmacological . Fo For r r ex ex exa am mp ple, in n n mi ice e e, ab ab be er erra ra ant nt t D D 3 3 3 r rec ecep pto tors rs e e exp x xpre ress ss ssio io on n in in h h hea ea art t t an nd d d in in n p p per erip ip iphe he h ra ral l l v va vasc sc cul ular ar sys ys ste te ems ms ms m m may ay y i i in n ncr cr crea a ase se s i i int nt tim im ma a pe pe perm rm rmea ea eab b bili li ity ty ty, , v v vas sc scul ul lar ar a r rem em mo od odel el lin n ng, g, atherosclerosi si is s s fo fo f rm rm rmat at tio io ion, n o o or r r th the e e po po p ss ss s ib b bil il i it it ity y y of of of p p pla la aqu qu que e e ru ru upt pt ptur ur ure e e by by by int nt nter er erac ac acti ti ting ng ng w w wit it ith h h re re reni ni n n, n risk. 41 Another possibility is that antipsychotic usage could predispose a patient to increased metabolic risk, accelerating the development of an AMI, although this seems unlikely in the context of our study. Had this been the case, our results would have shown progressive increase in AMI risk over the durations of antipsychotic exposure and a specifically greater risk for patients with a metabolic disorder ( Table 4) . Nevertheless, these hypotheses should be examined using biological models.
This study found that use of amisulpride, which is generally thought to be cardiovascular safe, 42 had the highest AMI risk of all the medications studied ( Table 3 & Supplemental Figure   1 ). Amisulpride is a unique dopamine receptor antagonist and different from other antipsychotics in that it has the highest selective affinity for D 3 receptors, 43 a property found by this study to be associated with greatest AMI risk. And while amisulpride has in fact been associated with AMI in one post-marketing survey, 44 its risk should not be overemphasized because this study only included a small number of cases taking amisulpride. After all, current study found an association between several antipsychotics and AMI risk.
Possibly due to their favorable extrapyramidal side-effect profiles and an increase in official approvals for their application in a wider variety of mental disorders, SGAs are rapidly supplanting FGAs in their use in clinical psychiatry in the United States. 12 The current study found, however, SGAs to carry greater risk for AMI than FGAs (AOR=1.63, 95% CI=1.29-2.05).
That SGAs have a higher affinity for D 3 receptors may partially explain this increased risk. 45 In addition, because SGAs have been associated with obesity and increased risk of stroke, 16 more research may be undertaken to reevaluate the cardiovascular safety of these increasingly popular drugs.
This study has several limitations. One limitation is that the study might still include n that it has the highest selective affinity for D 3 receptors, 43 a property found by y t thi hi is s st st stud ud udy y y to to to b be associated with greatest AMI risk. And while amisulpride has in fact been associated with AMI n n n o o one ne ne p p pos os st-t-t-m m mark k ket et etin ing survey, 44 its risk should n no ot ot b b be overemphas siz i i ed d b b be ec ecause this study only m n ncl l lu uded a sma mall ll ll n num umbe be b r r r of of of c c cas a ases es t t tak ak akin n ng g am mi isu u ulpr rid id de. A A Af ft fter er all ll, c cu cur r rren ent t t st t tud udy y y f fo foun un nd d an an a as sso so soci ci ciat at a io ion n n be be betw twee e en n s se ev ve era ral an an a ti ti tips ps psyc y ycho ho oti ti ics cs cs a a and nd d A AMI MI M r ris is i k. k k.
Possib ib bly ly ly d d due ue ue t to o o th t t ei ei ir r r fa fa f vo vo vora ra r bl bl b e ex ex e tr tr trap ap apyr yr yram am amid id idal al a s sid id ide-e-e ef ef e fe fe fect ct ct p pro ro rofi fi file le les s s an an and d an an an i i inc nc ncre re r ase in recurrent cases with an AMI history before 1997. Another is that it did not exclude patients prescribed long-acting antipsychotic drugs (<0.1% of the study population) whose pharmacokinetic properties show delayed onset and prolonged action. The study might have also included some non-AMI patients due to miscoding in the NHIRD, though one previous validation study found the positive predictive value and sensitivity of the diagnoses in NHIRD for major cardiovascular events to be high (88.4% and 97.3%, respectively). 46 To improve the diagnostic validity, we only identified patients who had been hospitalized or treated at an emergency department for an incident AMI. We also found that 83% of cases enrolled in our final analysis had been treated with percutaneous coronary intervention, fibrinolysis, antiplatelet/anticoagulant therapy, or bypass surgery within 30 days after the AMI events.
Another limitation might be because NHIRD only reports prescribed doses, not doses actually taken by the patients, patient nonadherence might have led to underestimates of the actual risk of antipsychotic use. Still another is that since only adult cases with schizophrenia, mood disorders or dementia were studied, our results might not be generalized to other populations, such as nonpsychiatric patients and children with autism or attention-deficit/hyperactivity disorders. In addition, fatality cases due to AMI may not be completely included into our analysis because we did not link to the National Mortality File Database in Taiwan. We might not have included all the cases of incident AMI initially presenting with out-of-hospital cardiac arrest, which has been found to constitute 0.3% of all the emergency visits in Taiwan. 47 However, because this is a caseonly study, missing cases with AMI would simply decrease the representativeness of the study instead of substantially biasing the results. Another limitation might be that because we used receptor-binding profiles obtained from in vitro studies, our findings on the association between effects on certain receptors with AMI risk might not reflect the actual relationships observed in antiplatelet/anticoagulant therapy, or bypass surgery within 30 days after the AMI MI I e e eve ve v nt nt nts. s s.
Another limitation might be because NHIRD only reports prescribed doses, not doses actually a ake ke en n n by by by t t the he he p p pat tie ie en nt nts s, patient nonadherence migh gh ht t t h h have led to unde de derest st tim im imat a es of the actual risk of f
an nti i ips p ychotic us use e. e Sti ti ill ll l a a ano no oth th ther er er is is t t tha ha hat si sin nce on on nly a a ad du ult c ca as ase es s w w wit ith h h s sc schi hi iz z zop ph phre re eni n nia, a, m m mo oo ood d d di di iso sord rd r e e ers or r d d dem em men enti tia a a w we were re e s s stu tud d die ed d, , ou u ur r r re re esu su sult lt lts s m mi migh gh ght t t no o ot t t be be e g g gen n ner r ral al ali iz ized ed ed t to o o ot ot othe he h r r r po po opu pu ula la ati ti t on on ns, s, s, su u uch h h as as no on onpsychiatric pa pa pati ti t en en e ts ts ts a and nd nd chi hi hild ld ldre re r n n n wi wi with th t a a aut ut utis is ism m m or or or at at a te te t nt nt n io o on-n-n de de defi fi f ci ci cit/ t/ t/hy hy ype pe pera ra ract ct ctiv iv ivit ity y y di di diso so sord rd rder e s. In the human body. Finally, the estimated AMI risk associated with antipsychotic use might be related to the indications (e.g., agitation, aggression, and risk-taking behaviors) for which an antipsychotic was prescribed. Hence our results might be confounded by indications. However, for each psychiatric patient, the past and the recent reasons associated with antipsychotic treatment were highly correlated. Confounding related to those reasons, including those unmeasured biological and psychosocial variables, should be able to be eliminated by the selfmatching in case-crossover design. Moreover, we used benzodiazepine drugs and nonbenzodiazepine hypnotics-sedatives which are often used to manage agitation and aggression, either one alone or in combination with antipsychotics-as negative controls to evaluate whether our findings were complicated by confounding by indications. If the association between antipsychotic use and acute risk for AMI found by our study design was spurious, then we should be able to observe that sedative use was also linked to the risk for AMI. In fact, our findings showed that use of benzodiazepine drugs and non-benzodiazepine hypnotics was not significantly associated with AMI risk (AOR=1.03, 95% CI=0.92-1.15; AOR=1.06, 95%
CI=0.95-1.18; respectively).
This study analyzed patient data of Taiwan. Asians may be more vulnerable to adverse drug effects because they metabolize drugs more slowly than other ethnic groups, 48 so there is a need for caution when extrapolating our results regarding Asian-specific responses to antipsychotic drugs.
Conclusion
This study found a significant association between antipsychotic treatment and risk of AMI.
Given the widespread use of antipsychotics in primary care and a lack of perception of such risk, <0.0 t tme m m nt nt n for co-medi dica cati n ons, s a a and out u u a a patient t vi v v i sits ts t . nd nd o o of do do dose se-d -dep pen ende de dent nt n e eff ffec e e .
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SUPPLEMENTAL MATERIAL
Number of Online-Only Tables: 5  Supplemental Table 1 . List of Selected Co-Medications. Abbreviations: D1, dopamine 1; D2, dopamine 2; D3, dopamine 3; D4, dopamine 4; 5-HT1A, serotonin 1A; 5-HT2A, serotonin 2A; 5-HT2C, serotonin 2C; 5-HT3, serotonin 3; 5-HT6, serotonin 6; 5-HT7, serotonin 7; α1, adrenergic alpha 1; α2, adrenergic alpha 2; M1, muscarinic 1; H1, histamine 1. * Herein the use of co-medication might reflect the condition being treated rather than the drug itself. † Adjustment for co-medications, and outpatient visits.
Supplemental
